

"Tote Board, Hollywood Park, Century, Inglewood, CA, US" by jondoeforty1 http://www.flickr.com/photos/jondoeforty1/2602455841 Licensed under CC BY 2.0 via Commons

Introduction to Biostatistics Lecture 6

Henrik Renlund

October 12, 2015



What shall we learn today?

Many analyses and concepts that relates to count data (tables).

For tables relating dichotomous data (event or non-event) what can be said about risk, both

- compared to a model (probability specification), and
- between subgroups?

For tables relating counts of a categorical variable, how can we test the distribution of values against

- a model, or
- between subgroups.

Dabigatran data

Dagbigatran is an anticoagulant used for e.g. stroke prevention in patients with atrial fibrillation. The following example only looks at side effects.

718 people were randomized to Dabigatran or placebo and observed for some set time for bleeding.

| id | intervention | bleeding |
|-----|--------------|----------|
| 1 | dabigatran | Yes |
| 2 | placebo | No |
| 3 | placebo | No |
| 4 | dabigatran | No |
| ÷ | : | ÷ |
| 718 | placebo | No |



Tabulated data

| | Bleeding | | | |
|---------------|----------|-----|-----|--|
| Yes No Sur | | | | |
| dabigatran | 27 | 320 | 347 | |
| placebo | 8 | 363 | 371 | |
| Sum | 35 | 683 | 718 | |

Measures for dabigatran:


- Risk (probability of an unwanted event)
 Risk of bleeding = 27/347 = 7.8%
- Odds (how much more likely it is, versus not, to experience an event)
 Odds of bleeding

$$=\frac{27/347}{320/347}=\frac{27}{320}=8.4\%$$

(Odds? Sometimes this is easier to model.)


Odds

For an event with probability p, the odds is p/(1-p).



Odds

For small probabilities: odds \approx probability.





More on odds

- if an event has odds θ , then its probability p is $p = \theta/(1+\theta)$
 - $\theta = 2$ corresponds to p = 2/3.
 - $\theta=1$ corresponds to p=1/2.
 - $\theta = 1/100$ corresponds to p = 1/101.
- in a betting game where you stand to win 1 unit of money, your stake S (if this is kept when winning) should not exceed the odds
 - 'expected' profit = $1\frac{\theta}{1+\theta} S\frac{1}{1+\theta} \ge 0$ is equivalent to $S \le \theta$
 - If you are offered x units of money for a game you think has odds 2 (in your favor) then do not bet more than 2x.
 Betting 2x makes the game "fair".
- there are multiple systems of betting (sports) 'odds', that are not odds in the sense of this course!

Relational measures

| | Bleeding | | | |
|---------------|----------|-----|-----|--|
| Yes No Sur | | | | |
| dabigatran | 27 | 320 | 347 | |
| placebo | 8 | 363 | 371 | |
| Sum | 35 | 683 | 718 | |

Measures for risk of dabigatran versus placebo

- (Risk ratio (RR) = $\frac{27/347}{8/371} \approx 3.6$)
- Odds ratio (OR) = $\frac{27/320}{8/363} \approx 3.8$
- Risk difference = $27/347 8/371 \approx 0.056$

Odds ratio (OR)

The OR contains no information about the probabilities. If you know the 'denominator' probability (p_2) then the 'numerator' probability (p_1) can be calculated

$$p_1 = \frac{\mathsf{OR} \cdot p_2}{1 + (\mathsf{OR} - 1) \cdot p_2}.$$


More importantly, for small values of p_2 and 'moderate' values of OR, one essentially has

$$p_1 \approx \mathsf{OR} \cdot p_2$$
.

| 'denominator' (p ₂) | Odds Ratio (OR) | | | | |
|---------------------------------|-----------------|-------|------|-------|-------|
| | 0.1 | 0.5 | 1 | 2 | 10 |
| 0.01 | 0.0010 | 0.005 | 0.01 | 0.020 | 0.092 |
| 0.05 | 0.0052 | 0.026 | 0.05 | 0.095 | 0.340 |
| 0.1 | 0.0110 | 0.053 | 0.10 | 0.180 | 0.530 |
| 0.5 | 0.0910 | 0.330 | 0.50 | 0.670 | 0.910 |

OR and probabilities

The blue dotted lines are the 'corresponding slopes'.



Fishers exact test

| | Bleeding | | | |
|------------|----------|-------------|-----|--|
| | Yes | No | Sum | |
| dabigatran | Х | (347-X) | 347 | |
| placebo | (35-X) | (683-347+X) | 371 | |
| Sum | 35 | (683) | 718 | |

Suppose that whether a person bleeds or not is complete independent of intervention. (H_0 : "odds ratio = 1".)


Then the 35 individuals who bled should be a random sample of the study population (of size 718) and we would expect that $X/35 = 347/718 \approx 48\%$.

We can calculate *exactly* what the distribution of X is *given* H_0 .

The p-value is the probability of a discrepancy the size of that between the observed and the expected.

p-value in Fishers exact test

Sum the red values to get p = 0.00045.





More on Fishers exact test

My software produced the following output:

Dabigatran_example

Fisher's Exact Test for Count Data

```
alternative hypothesis: true odds ratio is not equal to 1 95 percent confidence interval: 1.659358 9.877595 sample estimates: odds ratio
```

3.821942

p-value = 0.0004458

So odds ratio is between 1.7 and 9.9. (Allows for test of model.) Probabilities are small, so risk of dabigatran is (approx.) between 1.7 and 9.9 times larger than placebo risk.



What question did we answer?

Calculating the OR is a very 'standard' analysis.

It is worth reiterating that this is a relative measure and answers a question along the lines of

how much does the odds of bleeding - measured in units of the placebo odds - change with this drug? Answer: 3.83 (1.66–9.88).

The placebo risk is $p_2=8/371\approx 2.2\%$ so we can use an earlier formula to get $p_1=$ risk with dabigatran:

| OR | 1.66 | 3.83 | 9.88 |
|-------------|------|------|------|
| $p_1 pprox$ | 3.6% | 8.2% | 21% |
| $p_1 =$ | 3.5% | 7.8% | 18% |
| RR = | 1.6 | 3.6 | 8.3 |

In a sense this gives us a confidence interval p_1 but it is "too" wide since it takes into account the uncertainty of p_2 .



Absolute risk

What can we say about the absolut risk of bleeding with dabigatran?

This was covered by Lars in Lecture 3! (Genotype example.)

The risk estimate 27/347 = 0.078 has a standard error (SE) given by

$$\sqrt{\frac{0.078(1-0.078)}{347}} = 0.0144.$$

This yields a 95% confidence interval given by

$$(0.078 \pm 1.96 \cdot 0.0144) = (0.050, 0.11).$$

(This allows for test of model.)

Risk difference

What is the *difference* in risk between dabigatran and placebo? This has (almost) been covered by Lars. One needs to know that for two **independent** estimators (having SE_1 and SE_2) the SE for their difference is given by

$$\sqrt{\mathsf{SE}_1^2 + \mathsf{SE}_2^2}.$$

| Risk | Estimate | Standard error |
|------------|------------------------|---------------------------------------|
| dabigatran | $p_1 = 27/347 = 0.078$ | $\sqrt{p_1(1-p_1)/347}=0.0144$ |
| placebo | $p_2 = 8/371 = 0.022$ | $\sqrt{p_2(1-p_2)/371} = 0.0075$ |
| difference | $p_1 - p_2 = 0.056$ | $\sqrt{0.0144^2 + 0.0075^2} = 0.0162$ |

We get a 95% confidence interval for the difference with

$$(0.056 \pm 1.96 \cdot 0.0162) = (0.024, 0.088).$$

(This allows for test of model.)



Have we exhausted the Dabigatran example yet?

Summary of the dabigatran example:

| Quantity | Estimate | Confidence interval |
|----------------|----------|---------------------|
| p_1 | 0.078 | (0.050, 0.11) |
| $p_1 - p_2$ | 0.056 | (0.024, 0.088) |
| OR (p1 vs. p2) | 3.82 | (1.7, 9.9) |

Cosmetic skin testing

To prove a new product is hypoallergenic it should provoke no more skin reactions than current market leader.

To test a new product 40 individuals got both products applied to to patches of skin and observed for reaction (yes/no)

| id | new | market |
|----|-----|--------|
| 1 | no | no |
| 2 | yes | no |
| 3 | no | no |
| ÷ | ÷ | : |
| 40 | yes | yes |



Is the new product as good as the market leader?

The following table is *not* appropriate to answer that question.

| | no | yes |
|-----|----|-----|
| old | 22 | 18 |
| new | 32 | 8 |

The rows are dependent.

Note:

One can estimate (and get confidence intervals) for p_1 and p_2 (risk of skin reaction with new and old, respectively).

But it is harder to quantify the SE for risk difference and OR, due to the dependence.

McNemars test for paired data

| | new | | | |
|--------|--------|----|-----|--------|
| | | no | yes | \sum |
| market | no | 17 | 5 | 22 |
| | yes | 15 | 3 | 18 |
| | \sum | 32 | 8 | 40 |

McNemars test only considers the pairs were the results are different.

With new product there are 8 reactions but 3 of them would have happened anyway. The new product 'creates' 5 reactions.

Similarly, the market leader 'creates' 15 reactions. (15 benefits, 5 are worse off and 20 are unchanged.)

A test statistic is created using '5' and '15'. p-value for H_0 :'no difference' is approx 4%.



Other situations

Twins being randomized to intervention or placebo:

| | Placebo | | |
|--------------|-------------|-------------|-----|
| | | improvement | non |
| Intervention | improvement | a | b |
| | non | С | d |

Before/after data:

| | | Before | | | | |
|-------|-------|-----------|---|--|--|--|
| | | event non | | | | |
| After | event | а | b | | | |
| | non | С | d | | | |



Mendel's pea experiment

One of Mendels pea-experiments was a (dihybrid) cross between the genes for round/wrinkled seeds and yellow/green seeds.

| Туре | RY | RG | WY | WG | Sum |
|-----------|-----|-----|-----|----|-----|
| Count (O) | 315 | 108 | 101 | 32 | 558 |

According to his theory, these should appear in ratios of 9:3:3:1. So, we have a model for X= "the type":

| Value v | RY | RG | WY | WG |
|-------------|------|------|------|------|
| Prob(X = v) | 9/16 | 3/16 | 3/16 | 1/16 |



$$\chi^2$$
-tests

 χ^2 tests are applied to tabulated data (i.e. the 'counts'), typically categorical data.

Like the t-test, we can use χ^2 to compare a sample against a model or, compare 2 or more samples against each other.

 χ^2 -tests can be applied to all tables (non-paired data) presented so far.

 χ^2 tests typically calculate a test statistic Q according to the formula

$$Q = \sum \frac{(\text{observed - expected})^2}{\text{expected}}.$$

Q is compared to a χ^2 distribution with a parameter (degrees of freedom) that depends on the situation.

Comparing data to a model


χ^2 -analysis:

| Туре | RY | RG | WY | WG | Sum |
|-------------------------------|-------|-------|--------|--------|-------|
| Data (O) | 315 | 108 | 101 | 32 | 558 |
| H_0 model (p) | 9/16 | 3/16 | 3/16 | 1/16 | 1 |
| Expected $(E = 558 \times p)$ | 313.9 | 104.6 | 104.6 | 34.9 | 558 |
| Q, i.e. $(O - E)^2/E$ | 0.004 | 0.111 | 0.124 | 0.241 | 0.479 |
| Residuals $(O - E)/\sqrt{E}$ | 0.127 | 0.367 | -0.318 | -0.467 | |

If H_0 is correct then Q should be (approximately) $\chi^2(3)$. (3 = the number of categories -1.)

Mendels hypothesis seems ok

The observed test statistic 0.47 is compatible with H_0 .



Comparing distributions

A case control study of coronary heart disease and drinking (none, moderate, heavy). Cases were matched on age, gender and smoking habits.


| | non | moderate | heavy | sum |
|----------|-----|----------|-------|-----|
| cases | 34 | 80 | 18 | 132 |
| controls | 156 | 334 | 37 | 527 |
| sum | 190 | 414 | 55 | 659 |

Does drinking habits differ between cases and controls? If they do not (H_0) , their distributions should be close to


| non | moderate | heavy |
|-----------------|-----------------|---------------|
| 28.8% (190/659) | 62.8% (414/659) | 8.3% (55/659) |

cases

 χ^2



controls



Are drinking categories equidistributed for cases and controls?

| | non | moderate | heavy | Sum |
|--|-------|----------|-------|-------|
| observed cases | 34 | 80 | 18 | 132 |
| observed controls | 156 | 334 | 37 | 527 |
| sum | 190 | 414 | 55 | 659 |
| prop. (p=sum/659) | 0.29 | 0.63 | 0.08 | (1) |
| expected cases (132·p) | 38.1 | 82.9 | 11.0 | (132) |
| expected controls $(527 \cdot p)$ | 152.0 | 331.0 | 44.0 | (527) |
| Q cases ((ObsExp.) ² /Exp.) | 0.43 | 0.10 | 4.4 | Tot: |
| Q controls | 0.11 | 0.026 | 1.1 | 6.2 |

The test statistic Q = 6.2 should be compared to a χ^2 with $(rows-1)\times(columns-1)=1*2=2$ degrees of freedom. p = Prob(Q > 6.2) = 0.045.

So the difference between cases and controls is statistically significant.

The large sample size gives this test a lot of power (ability to find differences).


Do not forget to look at the estimates!

| | non | moderate | heavy |
|---------------------|------|----------|-------|
| proportion cases | 0.26 | 0.61 | 0.13 |
| proportion controls | 0.30 | 0.63 | 0.07 |
| proportion total | 0.29 | 0.63 | 0.08 |

Whether these differences are significant in any other sense is for the researcher to discuss.

Which categories deviate?

One can also look at the 'residuals'.



χ^2 on the dabigatran data

The χ^2 test can also be applied to our dabigatran data.

It tests if the distribution of complications (bleeding/not) is the same for the two groups.

Output from my software:

#

```
# Pearson's Chi-squared test with Yates'
# continuity correction
#
# data: bord
```

(Recall that Fisher's exact test gave p = 0.0004458.)

X-squared = 11.05, df = 1, p-value = 0.0008869



Adjusting for a confounder

Comparison of open surgery (OS) and percutaneous nephrolithotomy (PN) for removal of kidney stones.

(Data illustrates Simpson's paradox.)

Success
Failure
Odds (for success)

Odds ratio (OS / PN)

| То | tal | Small stones | | Large | stones | | |
|-----|-----|--------------|-----|-------|--------|--|--|
| OS | PN | OS | PN | OS | PN | | |
| 273 | 289 | 81 | 234 | 192 | 55 | | |
| 77 | 61 | 6 | 36 | 71 | 25 | | |

6.5

2.1

Adjusted for size

2.7

2.2

1.2

Here it seems like we should adjust for stone size.

The Mantel-Haenszel test is a way to analyse several contingency tables.

4.7

0.75

13.5

3.5



Adjusting for multiple confounders

In observational studies we typically gather more information. E.g.

| Ind. | Bleeding | DE Dose | Age | Gender | Weight | |
|------|----------|---------|-----|--------|--------|--|
| 1 | Yes | 50 | 75 | М | 83 | |
| 2 | No | 75 | 64 | F | 77 | |
| : | : | : | : | : | : | |

When medicine is not randomized a simple cross tabulation analysis of 'Bleeding' versus 'DE Dose' is likely to be confounded.

One way to deal with this is to do a logistic regression. More on that in Lecture 10.



References

- Chapters 23-25: Petrie & Sabin. *Medical Statistics at a Glance*, Wiley-Blackwell (2009).
- Grant, R. L.: Converting an odds ratio to a range of plausible relative risks for better communication of research findings, BMJ 348 (2014) 7 pages.